side-btn

Wake Up To Life

A Novel Therapy In Insomnia1,2

DAYVIGO is a new prescription medicine for adults who have trouble falling and/or staying asleep (insomnia).

Efficacy3,4

Efficacy of Dayvigo is tested and principally supported by 2 adequate & well-controlled Phase 3 studies i.e. SUNRISE 1 & SUNRISE 2 that evaluated two doses of Lemborexant (LEM5 and LEM10).

View the Data

Safety5-7

Safety of Dayvigo has been tested in various scenarios. Endpoints like physical dependence, rebound insomnia and abuse liability have also been evaluated.

View the Data

Resources

As you explore the website and learn more about Dayvigo, be sure to take a look at the interesting tools and resources we’ve provided to mange your patients with insomnia.

Click here for Resources

References:

  1. Dayvigo (Lemborexant) India Prescribing Information: 2021.
  2. Beuckmann CT, Suzuki M, Ueno T, Nagaoka K, Arai T, Higashiyama H. In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist. J Pharmacol Exp Ther. 2017;362(2):287-95.
  3. Rosenberg R, Murphy P, Zammit G, et al. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial. JAMA Netw Open. 2019;2(12):e1918254.
  4. Kärppä M, Yardley J, Pinner K, Filippov G, Zammit G, Moline M, Perdomo C, Inoue Y, Ishikawa K, Kubota N. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep. 2020;43(9):zsaa123.
  5. Murphy P, Kumar D, Zammit G, Rosenberg R, Moline M. Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening. J Clin Sleep Med. 2020;16(5):765-773.
  6. Vermeeren A, Jongen S, Murphy P, Moline M, Filippov G, Pinner K, Perdomo C, Landry I, Majid O, Van Oers ACM, Van Leeuwen CJ, Ramaekers JG, Vuurman EFPM. On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. Sleep. 2019 Apr 1;42(4):zsy260.
  7. Asakura S, Shiotani M, Gauvin DV, Fujiwara A, Ueno T, Bower N, Beuckmann CT, Moline M. Nonclinical evaluation of abuse liability of the dual orexin receptor antagonist lemborexant. Regul Toxicol Pharmacol. 2021 Dec;127:105053